Not yet recruitingObservationalLast updated Aug 12, 2026

A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC

A Prospective, Observational, Multicenter, Post Marketing Surveillance Study to Assess Safety of Durvalumab in Indian Adult Patients With Resectable Non-Small Cell Lung Cancer (NSCLC)

Overview

ClinicalTrials.gov ID: NCT07760519
Lead Sponsor: AstraZenecaINDUSTRY
Brief Summary: This will be a single-arm, multicenter, prospective, observational, real-world study and the data source is the patients' medical record at each site. A total of 78 patients will be enrolled in the study.
Study Type: Observational

Status

Overall Status: Not yet recruiting
Start Date: Sep 30, 2026Estimated
Primary Completion Date: Apr 30, 2030Estimated
Completion Date: Apr 30, 2030Estimated

Study Record Dates

First Submitted: Jun 17, 2026
First Submitted that Met QC Criteria: Aug 10, 2026
First Posted: Aug 12, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 10, 2026
Last Update Posted: Aug 12, 2026Actual
Last Verified: Aug 2026

NCT04416633Completed

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

NCT04068168Completed

Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)

NCT04667312Completed

Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom

NCT03995875Completed

Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC

NCT05456867Active, not recruiting

A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

NCT03693300Completed

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer